ClinicalTrials.gg
WithdrawnNCT07583030Updated Oct 2, 2026

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

An Early Phase 1 interventional study of LVIVO-TaVec400 product in Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD) and Progressive Multiple Sclerosis (PMS), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Withdrawn at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionLupus Erythematosus, SystemicRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Erythematosus, Systemic
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lupus Erythematosus, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
pipeline strategy change
Updated Oct 2, 2026Now WithdrawnStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Enrollment
11th of 11
0 · median 12
Started
2026
with 4 others
Phase 1
7 of 11
5 open now
Registered
10th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 11th largest by enrollment, is one of 5 that started in 2026, is one of 7 in phase 1, and was the 10th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, or all of them as a file.
02

Study summary

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.

Read the detailed description

This is a prospective, single-arm, open-label dose-escalation and dose-expansion study, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the LVIVO-TaVec400, an in vivo chimeric antigen receptor (CAR) -T cell therapy in subjects with relapsed/refractory autoimmune diseases. The subject who meets the defined eligibility criteria will follow the sequential stages: screening, treatment (LVIVO-TaVec400 infusion) and follow-up (Up to 15 years).

03

Conditions studied

  • Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)
  • Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)
  • Progressive Multiple Sclerosis (PMS)
  • Relapsed/Refractory Myasthenia Gravis(r/r MS)

Keywords

  • Relapsed/Refractory autoimmune diseases
04

In context

Lupus Erythematosus, Systemic Reclassified

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.

Compared within Lupus Erythematosus, Systemic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in clinical studies.
  • Age 18-65 years.
  • Adequate organ function at screening.
  • Clinical laboratory values meet criteria at screening visit.

    r/r SLE:

  • Patients meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) OR 2012 Systemic lupus international collaborating clinics (SLICC) classification criteria for SLE at least 6 months before screening.
  • At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smith antibody should be positive.
  • Fulfill SLE conditions.

    r/r IgG4-RD:

  • Patients meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for IgG4-RD.
  • Fulfill relapsed/refractory IgG4-RD conditions.
  • Patients have active disease: IgG4-RD Response Index (RI) ≥2.

Progressive MS:

  • Diagnosis of MS according to 2017 revised McDonald criteria.
  • Progressive MS according to clinical course criteria revised in 2013.
  • Presence of Cerebrospinal fluid (CSF) oligoclonal bands (OCBs) or elevated IgG Index at screening.

    r/r MG:

  • Diagnosis of MG.
  • Myasthenia Gravis Foundation of America (MGFA) Class II-IV.
  • Positive AChR-IgG or MuSK-IgG at screening.
  • Fulfill refractory MG conditions.

Exclusion criteria

Exclusion Criteria:

  • Active infections such as hepatitis and tuberculosis.
  • Coexist other or inflammatory diseases.
  • Severe underlying diseases such as tumor, uncontrolled diabetes and severe heart diseases.
  • Female subjects who are pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving LVIVO-TaVec400 treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LVIVO-TaVec400 product

    The dose escalation stage includes 4 dose level: DL1,DL2,DL3, DL4.

    Biological: LVIVO-TaVec400 product

Interventions

  • BiologicalLVIVO-TaVec400 product

    Each subject will be given a single-dose LVIVO-TaVec400 via intravenous infusion.

07

What researchers measure

Primary outcomes

  1. The incidence of Dose-limiting toxicity (DLT)

    DLTs are severe adverse events refers to any untoward medical occurred in a subject participated in a clinical investigation, which has a causal relationship with the treatment and will limit the dose escalation.

    Time frame: 28 days after LVIVO-TaVec400 infusion (Day 1)

  2. The incidence, severity of Adverse events (AEs)

    An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.

    Time frame: Minimum 13 weeks after LVIVO-TaVec400 infusion (Day 1)

  3. The incidence, severity of Treatment-related Adverse event (TRAE)

    An treatment-related adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which has a causal relationship with the treatment.

    Time frame: Maximum 15 years after LVIVO-TaVec400 infusion (Day 1)

  4. Maximum concentration (Cmax) in peripheral blood

    Maximum concentration (Cmax) in peripheral blood

    Time frame: Maximun 5 years after LVIVO-TaVec400 infusion (Day 1)

  5. Time of maximum concentration (Tmax) in peripheral blood

    Time of maximum concentration (Tmax) in peripheral blood

    Time frame: Maximum 5 years after LVIVO-TaVec400 infusion (Day 1)

  6. Area under the concentration-time curve (AUC) in peripheral blood

    Area under the concentration-time curve (AUC) in peripheral blood

    Time frame: Maximum 5 years after LVIVO-TaVec400 infusion (Day 1)

  7. Recommended Dose regimen finding

    Determine the Recommended Dose regimen established through dose exploratory.

    Time frame: Maximum 104 weeks after LVIVO-TaVec400 infusion (Day 1)

Secondary outcomes

  1. Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores from baseline for r/r SLE subjects

    The SLEDAI-2K scale is a cumulative index used to assess disease activity across 24 different disease descriptors in patients with SLE. A total score ranges between 0 and 105, with a higher score representing a more significant degree of disease activity.

    Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)

  2. Change in IgG4-RD Response Index (IgG4-RD RI) from baseline for r/r IgG4-RD subjects

    The IgG4-RD scale is a cumulative index used to assess disease activity across 25 different disease descriptions in patients with IgG4-RD. A total score ranges between 0 and 75, with a higher score representing a more significant degree of disease activity.

    Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)

  3. Change in Expanded Disability Status Scale (EDSS) scores from baseline for PMS subjects.

    The EDSS is a scoring system used to quantify and monitor the progression of physical disability in patients with multiple sclerosis. The total score ranges from 0 to 10, with higher scores representing a worse outcome.

    Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)

  4. Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores from baseline for r/r MG subjects.

    The MG-ADL is a patient-reported tool that quantifies the severity of myasthenia gravis symptoms based on daily functions. The total score ranges from 0 to 24, with higher scores representing a worse functional status.

    Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)

  5. Change in Quantitative Myasthenia Gravis (QMG) scores from baseline for r/r MG subjects.

    The QMG is a standard clinical tool used to quantify the severity of myasthenia gravis through objective muscle testing. The total score ranges from 0 to 39, with higher scores representing a worse clinical status.

    Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)

08

Study locations

4 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Apr 2026 → Sep 2026, primary completion Sep 2028 → Sep 2026 and completion Sep 2041 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 13, 2026
StartActual
Sep 23, 2026was Apr 2026
Primary completionActual
Sep 23, 2026was Sep 2028
CompletionActual
Sep 23, 2026was Sep 2041
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn pipeline strategy change
changed Oct 2, 2026
Sites
1 site removed
Show 1 removed
  • Beijing Tiantan Hospital, Capital Medical University · Beijing, China
Oct 2, 2026
Start date
Apr 20, 2026→Sep 23, 2026 (actual)
Oct 2, 2026
Primary completion
Sep 20, 2028→Sep 23, 2026 (actual)
Oct 2, 2026
Study completion
Sep 20, 2041→Sep 23, 2026 (actual)
Oct 2, 2026
Enrollment
44 (estimated)→0 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Withdrawn
    Why stopped pipeline strategy change
    1 site removed
    Show 1 removed
    • Beijing Tiantan Hospital, Capital Medical University · Beijing, China
    Start date Apr 20, 2026→Sep 23, 2026 (now actual)
    Primary completion Sep 20, 2028→Sep 23, 2026 (now actual)
    Study completion Sep 20, 2041→Sep 23, 2026 (now actual)
    Enrollment 44 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07583030
Collaborators
Nanjing Legend Biotech Co.
Responsible party
Qiubai Li (Director, Head of Department of Rheumatology and Immunology, Principal Investigator, Professor, Wuhan Union Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
May 13, 2026
Start date
Sep 23, 2026
Primary completion
Sep 23, 2026
Completion
Sep 23, 2026
Last update
Oct 2, 2026

Study contacts

Qiubai Li
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion